Abstract Our understanding of the pathogenesis of cerebellar ataxias has started several decades ago and is continuously growing. The numerous mechanisms of cerebellar dysfunction are being discovered by numerous groups of researchers worldwide. Neuronal damage results from a complex interaction of metabolic pathways, which leads to symptoms observed in cerebellar disorders. The main mechanisms at the molecular level are the following: impairment of DNA repair and replication, deregulation of transcription/deficits of processing/transport of RNA, abnormal protein transport and misfolding, aggregates both at the nuclear and cytosolic level, activation of caspases, apoptosis, involvement of autophagic mechanisms, oxidative stress and mitochondrial dysfunction, excitotoxicity, abnormal lipid metabolism, impaired axonal transport and vesicle trafficking, and defects of the neurotransmission. The convergence of the current clinical classification with molecular findings is expected. This integration is a basic substrate for the rationale development of therapies.
11. Abnormal fatty acid metabolism 12. Disorders of neurotransmission Figure 2 illustrates these pathways. A main field of investigations is on SCAs. Currently, 28 SCAs are identified [3] . In several SCAs, the expansion of CAG tracts in certain genes results in transcription of proteins with abnormally long polyQ (polyglutamine) inserts [4] . Such a mechanism is shared with Huntington's disease with stroke-like episodes) MEERF (myoclonus epilepsy with ragged red fibers).
X-linked ataxias
Fragile-X tremor ataxia syndrome Arts syndrome X-linked adrenoleukodystrophy (X-ALD) Rett syndrome Ataxia-dementia Ataxia-Deafness syndrome Sideroblastic anemia and spinocerebellar ataxia (ABC7) Deficit in pyruvate dehydrogenase E1-alpha Pelizaeus-Merzbacher allelic variant (HD) and spinal bulbar muscular atrophy (SBMA). Proteins form aggregates which contribute to neuronal loss. Expanded polyQ tracts participate in the formation of partially unfolded proteins [4] . Neurological deficits of polyQ repeat disorders appear for expanding tracts exceeding the critical value of 35-45 glutamines [4, 5] . Several models have been developed to recapitulate the molecular mechanisms occurring in cerebellar disorders, ranging from in vitro studies to complex animal models, each of them having advantages and disadvantages for translational research [6] . In vitro experiments indicate that proteasomes are unable to digest polyQ tracts [7] . Aggregates sequester proteasomes, ubiquitin, polyQ fragments and recruit HSP70 [7] . Therefore, essential proteins are depleted from the cells, an event which contributes to cell vulnerability [7] . Expanded polyglutamine tracts decrease the dimerization of TBP (TATA box protein) and enhance the binding to the transcription factor TFIIB [3] . The consecutive depletion of TFIIB is another factor causing neural susceptibility. SCA7 is an example of cerebellar disorder associated with defects of acetylation/deacetylation [8] . Mutant ataxin-7 targets the process of chromatin remodeling, causing 
/ataxia syndrome, MSA/sOPCA multiple system atrophy/sporadic olivopontocerebellar atrophy, ILOCA idiopathic late-onset cerebellar atrophy, CJD: CreutzfeldtJakob disease, GSS GerstmannSträussler-Scheinker disease transcriptional down-regulation. Ataxin-7's normal function as a transcription factor may explain the selective vulnerability of specific neuronal populations in SCA7 [9] . Other proteins, such as ataxin-1, involve both transcriptional regulation and RNA splicing [3] . Ataxin-2 interferes with the metabolism of RNA as a result of an interaction at the level of polyribosomes [10] . Ataxin-3 is also implicated in transcriptional deregulation. The protein acts as a repressor of transcription [3] . Ataxin-3 is closely linked to the phenomenon of ubiquitination/deubiquitination [11] . Protein cleavage is caspase-dependent and this cleavage boosts neuronal loss, suggesting that therapies targeting the cleavage of ataxin-3 might slow the disease progression in SCA3 [12] .
Impairment of neurotransmission is another mechanism shared by several cerebellar disorders. Impairment of glutamatergic/calcium signaling has been pointed in various sporadic and genetic ataxias, including SCA6, SCA13, or SCA27. SCA6 is associated with a CAG expansion in the CACNA1A subunit of the voltage-gated calcium channel P/Q CaV2.1. Increase in calcium signaling contributes to a gain-of-function, as well as translocation of a fragment to the nucleus [3, 13] . The glutamate transporter EAAT4 is stabilized by beta-III spectrin, whose mutations cause SCA5 [14] . Decreased reuptake of glutamate contributes to the cascade of NMDA and AMPA-mediated excitotoxicity [15] . Further studies are needed to confirm that SCA20 is also related to an overflow of glutamate [3, 16] . Mutations of the KCNC3 voltage-gated potassium channel (SCA13) affect directly the depolarization of neuronal membranes.
We are at the beginning phase of the integration of the clinico-genetic classification with molecular pathways involved in the pathogenesis of each family or subtype of cerebellar disorders. A reshaping of the clinico-genetic classification taking into account the molecular discoveries is likely to emerge soon. This fusion would have important consequences in terms of management, therapies, and future investigations in cerebellar research. In most cases, therapies of devastating ataxic disorders have remained purely symptomatic, because of (1) the lack of understanding of the molecular deficits, (2) the inability to identify the critical pathway(s) for each disorder, and (3) as a result of the use of models of cerebellar disorders which have brought non-relevant information for the development of therapies. Several therapeutic lines have now been drawn: modulation of gene expression and transcriptional tuning, changing the clearance of a mutant protein, making the protein less toxic, action upon chaperones, use of transglutaminase inhibitors, effects on caspase activation, effects on mitochondrial function and oxidative damage [17] . Development of therapies of sporadic ataxias might take an unexpected benefit from these investigations. The reverse is also true. For instance, there is hope that looking beyond the traditional mechanism of glutamate-receptordriven excitotoxicity could be very useful in stroke models [18] . There are growing evidence that ionic imbalance contributes to cell death; hence, the ongoing studies on sodium-calcium exchangers, hemichannels, volumeregulated anion channels, acid-sensing channels, transient receptor potential channels, nonselective cation channels, and signaling cascades [18] . New insights in the molecular pathogenesis of sporadic and hereditary ataxias open also now doors towards the unraveling of the myriad of secrets of the cerebellar circuits. Fig. 2 . Molecular pathways involved in hereditary cerebellar ataxias and which contribute to DNA/RNA/protein defects ending in cell death. Several neurons are illustrated, as well as a glial cell. The various pathophysiological processes may involve some specific categories of cells, according to the disease considered. In some disorders, the molecular pathogenesis still remains to be elucidated. In some instances, organelles are represented in association with a specific disorder, when this latter is critically linked to the given intracellular element, such as mitochondria for Friedreich ataxia (FA). Keymechanisms affect DNA, RNA, apoptosis, impairment of proteasome degradation, calcium homeostasis, mitochondrial dysfunction, axonal transport, trafficking of vesicles, excitotoxic cascades/oxidative damage, dysfunction of ion channels, deficits of neurotransmission. Abbreviations: SBMA spinal bulbar muscular atrophy, HD Huntington's disease, DRPLA dentatorubral-pallidoluysian atrophy, FMR2 fragile X mental retardation gene, TATA TATA box binding protein, POLII RNA polymerase II, HSP heat shock proteins, Ub ubiquitin; Mitochondria: Polγ polymerase-gamma, mtDNA mitochnondrial DNA, SOD superoxide dismutase, GPX glutathione peroxidase, ABC7 ATP-binding cassette 7, AVED ataxia with vitamin E deficiency, CACNA1A voltage-dependent calcium channel P/Q type (alpha 1A subunit); KCNC3 potassium voltage-gated channel (subfamily C member 3), SERCA Sarco/endoplasmic reticulum Ca 2+ -ATPase, ITPR1 inositol 1,4,5-triphosphate receptor (type 1), HDL highdensity lipoprotein, VLDL very low-density lipoprotein, IDL intermediate-density lipoprotein
